Skip to main content
    L

    Liminatus Pharma, Inc. Class A Common Stock (LIMN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.81
    -0.16 (-5.39%)

    Market Cap: $3.99M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Liminatus Pharma, Inc. Class A Common Stock (LIMN) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Liminatus Pharma, Inc. Class A Common Stock (LIMN) has a market cap of $3.99M and an enterprise value of $2.41M. Its share count is up 107.71% from a year earlier. It holds $1.57M more cash than debt, 39.47% of its market cap.

    Total Valuation

    Enterprise value is 39.47% below the market cap, as cash exceeds debt.

    Market Cap$3.99M
    Enterprise Value$2.41M
    Latest price (Nov 17, 2026)$2.81

    Key Dates

    Last Earnings DateAug 14, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 34.44% in the quarter ended Jun 30, 2026 and grew 159.50% a year over 2 years.

    Shares Outstanding967.97K
    Shares Change (YoY)+107.71%
    Shares Change (QoQ)+34.44%
    Share Count Growth (2Y CAGR)+159.50%

    Price Statistics

    The stock is down 94.75% over 52 weeks and trades 15.62% below its 50-day average.

    Beta (1Y)0.66
    52-Week Change-94.75%
    1-Month Change-9.65%
    3-Month Change-49.69%
    6-Month Change-70.42%
    Total Return (1Y)-94.75%
    Return vs SPY (1Y)-106.50%
    Max Drawdown (1Y)-97.54%
    Sharpe Ratio (1Y)-1.72
    Correlation with SPY (1Y)0.05
    50-Day Average$3.33
    200-Day Average$9.21
    52-Week Range$2.40 to $141.50
    RSI (14 Days)44.0
    Average Volume (20 Days)31.30K

    Financial Position

    Current assets cover 1.12x current liabilities, and total debt is 4.80x shareholder equity.

    Current Ratio1.12x
    Quick Ratio1.12x
    Debt / Equity4.80x
    Interest Coverage-72.16x

    Returns and Efficiency

    Return on invested capital is -247.19% and return on equity is -4274.79% over the last 12 months.

    Return on Equity (ROE)-4274.79%
    Return on Assets (ROA)-377.55%
    Return on Invested Capital (ROIC)-247.19%
    Return on Capital Employed (ROCE)-1501.38%

    Scores

    LIMN has a Piotroski F-Score of 1 of 9, in the weak band of 0 to 2.

    Piotroski F-Score1 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue was $0 over the last 12 months.

    Revenue$0
    Gross Profit$255
    Operating Income-$4.33M
    Pretax Income-$12.85M
    Net Income-$12.85M
    EBIT-$5.45M
    Reported EPS (TTM)-$837.61

    Trailing 12 months through Jun 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 8.84% of the $3.40M in total assets.

    Cash and Equivalents$3.02M
    Total Debt$1.44M
    Net Cash$1.57M
    Net Cash Per Share$1.63
    Working Capital$352.04K
    Shareholder Equity$300.61K
    Book Value Per Share$0.31
    Total Assets$3.40M
    Total Liabilities$3.10M

    Balance sheet as of Jun 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$3.97M
    FCF Per Share-$2.97
    Depreciation and Amortization$2.07K

    Trailing 12 months through Jun 30, 2026.

    Full cash flow statement

    Dividends and Yields

    LIMN does not pay a dividend.

    Buyback Yield-131.81%
    Shareholder Yield-131.81%

    Stock Splits

    The last split was a 1-for-50 reverse split on Aug 21, 2026.

    Last Split DateAug 21, 2026
    Split TypeReverse split
    Split Ratio1:50

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About LIMN

    What is LIMN's market cap?

    Liminatus Pharma, Inc. Class A Common Stock has a market cap of $3.99M. Its enterprise value, which adds debt and subtracts cash, is $2.41M.

    How many shares of LIMN are outstanding?

    Liminatus Pharma, Inc. Class A Common Stock has 967.97K shares outstanding. The count is up 107.71% from a year earlier.

    Does LIMN pay a dividend?

    No. Liminatus Pharma, Inc. Class A Common Stock does not pay a dividend.

    How much debt does LIMN have?

    Liminatus Pharma, Inc. Class A Common Stock has $1.44M of total debt and $3.02M of cash and equivalents, a net cash position of $1.57M.